We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Computer Model Identifies RNA Splicing Enhancers

By Biotechdaily staff writers
Posted on 25 Jul 2002
Researchers have found a way to predict which mutations in a gene's exons, those sections of the RNA which code for proteins, are likely to cause the exons to be skipped by the splicing machinery, which typically results in inactivation of the gene's product and can lead to disease. More...
This discovery was reported July 11, 2002, in the online journal Science Express.

Messenger RNA (mRNA) molecules contain strings of genetic material called exons, which code for proteins, and introns, which do not. Introns are removed from mRNA by a splicing mechanism that joins exons together. RNA splicing determines which segments of the gene end up being expressed and which do not.

The purpose of the study carried out at the Massachusetts Institute of Technology (MIT, Cambridge, USA; www.mit.edu) was to identify exonic splicing enhancers (ESEs). These are short RNA sequences that, when present in the exons of a human gene, enhance the splicing of the exons and thereby increase the proportion of mRNAs that contain them.

A computational method was developed, called RESCUE-ESE, that predicts which sequences have ESE activity by statistical analysis of exon-intron and splice site composition. When large datasets of human gene sequences were used, this method identified ten predicted ESE motifs. Representatives of all ten motifs were found to possess enhancer activity in vivo, whereas point mutants of these sequences exhibited sharply reduced activity.

"We developed a computational method to predict which sequences would function as ESEs, and then did experiments to test these predictions and found that all of the sequences predicted to function as splicing enhancers did indeed have this activity,” said senior author Dr. Christopher Burge, assistant professor in the biology department at MIT. "Eventually, we hope to be able to fully understand and model the process by which exons and introns are identified by the human RNA splicing machinery.”




Related Links:
MIT

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.